Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2026-02-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Year-end report January – December 2025' and contains comprehensive financial statements, including income statements, balance sheet data, and management commentary on business performance and outlook. It covers a full fiscal year period (January to December 2025) and provides detailed financial metrics (Revenue, EBITDA, R&D costs, etc.). While it is a year-end report, it functions as a comprehensive financial report for the period, fitting the definition of an Interim/Quarterly Report (IR) in the context of financial reporting standards where year-end reports are often categorized alongside interim reports if they are not the full 10-K/Annual Report filing. Q4 2025
2026-02-20 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) from the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding for Xbrane Biopharma AB by Göran Westman, specifically noting that the holding has crossed the 5% threshold. This is a classic major shareholding notification.
2025-11-25 Swedish
Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a company's decision to issue warrants as part of a financing solution (a loan agreement). It details the number of warrants, the terms of the issue, the impact on share capital, and the rationale for the financing. This falls under the category of capital and financing updates, specifically related to share-based financing instruments.
2025-11-24 English
Xbrane Biopharma beslutar om emission av 420 517 teckningsoptioner till Fenja Capital II A/S inom ramen för villkorad finansieringslösning
Share Issue/Capital Change Classification · 100% confidence The document is an announcement regarding a directed share issue (teckningsoptioner/warrants) to Fenja Capital II A/S as part of a financing arrangement. It details the terms of the issuance, the impact on share capital, and the rationale behind the financing. While it discusses a capital change, it is primarily an announcement of a financing event. Given the specific nature of the transaction (issuance of warrants/options for financing), it fits best under 'Capital/Financing Update'.
2025-11-24 Swedish
XBRANE UPPDATERAR TIDPLAN FÖR ÅTERINSÄNDNING AV BLA FÖR SIN RANIBIZUMAB-BIOSIMILAR TILL FDA
Legal Proceedings Report Classification · 100% confidence The document is a short press release (under 5,000 characters) issued by Xbrane Biopharma regarding an update to their regulatory timeline for a BLA submission to the FDA. It explicitly mentions that the information is being disclosed in accordance with the EU Market Abuse Regulation and provides a link to a PDF file. Following the 'Menu vs Meal' rule, this is an announcement of a regulatory update rather than a formal regulatory filing or report itself, making it a Regulatory Filing (RNS) or a general announcement.
2025-11-19 Swedish
XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
Legal Proceedings Report Classification · 100% confidence The document is a short press release (under 5,000 characters) issued by Xbrane Biopharma regarding the timing of a BLA resubmission to the FDA. It functions as a regulatory announcement under the EU Market Abuse Regulation, providing a corporate update on operational timelines rather than a full financial report or legal proceeding document. Given its nature as a general corporate announcement regarding regulatory status, it fits best under the RNS (Regulatory Filings) category.
2025-11-19 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.